Evidence map›Paper›PMID 33761087›Full record

ArticleMolecular biology reports2021

Differential expression of protein disulfide-isomerase A3 isoforms, PDIA3 and PDIA3N, in human prostate cancer cell lines representing different stages of prostate cancer.

Maria Araceli Diaz Cruz, Sandra Karlsson, Ferenc Szekeres, Maria Faresjö, Dan Lund, Dennis Larsson

Open access · hybridAbstract read
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The leader of the capsid protein fromJournal of virology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. ERp57/PDIA3: new insight.Cellular & molecular biology letters · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Maria Araceli Diaz CruzResearch School of Health and Welfare, School of Health and Welfare, University of Jönköping, Jönköping, Sweden. Maria-Araceli.Cruz@ju.se.ORCID http://orcid.org/0000-0002-0045-2133
Sandra KarlssonDepartment of Natural Science and Biomedicine, School of Health and Welfare, University of Jönköping, Jönköping, Sweden.
Ferenc SzekeresDepartment of Biomedicine, School of Health Sciences, University of Skövde, Skövde, Sweden.
Maria FaresjöDepartment of Natural Science and Biomedicine, School of Health and Welfare, University of Jönköping, Jönköping, Sweden.
Dan LundDepartment of Natural Science and Biomedicine, School of Health and Welfare, University of Jönköping, Jönköping, Sweden.
Dennis LarssonSahlgrenska University Hospital, Gothia Forum - for Clinical Research, Gothenburg, Sweden.
Jönköping University · SESahlgrenska University Hospital · SEUniversity of Skövde · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is a highly heterogeneous and unpredictable progressive disease. Sensitivity of PCa cells to androgens play a central role in tumor aggressiveness but biomarkers with high sensitivity and specificity that follow the progression of the disease has not yet been verified. The vitamin D endocrine system and its receptors, the Vitamin D Receptor (VDR) and the Protein Disulfide-Isomerase A3 (PDIA3), are related to anti-tumoral effects as well as carcinogenesis and have therefore been suggested as potential candidates for the prevention and therapy of several cancer forms, including PCa. In this study, we evaluated the mRNA expression of VDR and PDIA3 involved in vitamin D signaling in cell lines representing different stages of PCa (PNT2, P4E6, LNCaP, DU145 and PC3). This study further aimed to evaluate vitamin D receptors and their isoforms as potential markers for clinical diagnosis of PCa. A novel transcript isoform of PDIA3 (PDIA3N) was identified and found to be expressed in all PCa cell lines analyzed. Androgen-independent cell lines showed a higher mRNA expression ratio between PDIA3N/PDIA3 contrary to androgen-dependent cell lines that showed a lower mRNA expression ratio between PDIA3N/PDIA3. The structure of PDIA3N differed from PDIA3. PDIA3N was found to be a N-truncated isoform of PDIA3 and differences in protein structure suggests an altered protein function i.e. cell location, thioredoxin activity and affinity for 1,25(OH)

Indexed as

Amino Acid SequenceBase SequenceCell Line, TumorGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansIsoenzymesMaleNeoplasm StagingProstatic NeoplasmsProtein Disulfide-IsomerasesRNA, MessengerIsoenzymesPDIA3 protein, humanProtein Disulfide-IsomerasesRNA, MessengerAndrogen dependencyPDIA3PDIA3NProstate cancerVDRVitamin D

Identifiers

PMID33761087
PMCPMC8060222
OpenAlexW3138912681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.